Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 5/20 | 0.54 |
| ▸ | GSK3B | P49841 | 13/20 | 0.49 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12954498 | 0.83 | CDK2 (0.80) | CDK2GSK3BCCNE1 | |
| SCHEMBL13122813 | 0.78 | CDK2 (0.77) | CDK2GSK3BCCNE1 | |
| SCHEMBL6892832 | 0.78 | GSK3B (0.63) | CDK2GSK3BCCNE1 | |
| SCHEMBL1918959 | 0.74 | GSK3B (0.55) | CDK2GSK3BCCNE1 | |
| SCHEMBL1918027 | 0.73 | GSK3B (0.66) | CDK2GSK3BCCNE1 | |
| Hydrochloric Acid SCHEMBL6895081 | 0.72 | GSK3B (0.64) | CDK2GSK3BCCNE1 | |
| SCHEMBL7893839 | 0.72 | CSNK1E (0.46) | CDK2GSK3BCCNE1HTR2ADRD3 | |
| SCHEMBL12953408 | 0.72 | CDK2 (0.81) | CDK2GSK3BCCNE1 | |
| SCHEMBL14043450 | 0.72 | CDK2 (0.63) | CDK2GSK3BCCNE1 | |
| SCHEMBL1918958 | 0.71 | CDK2 (0.58) | CDK2GSK3BCCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040048849-A1 | Cyclin-dependent kinase (cdk) and glycolene synthase kinase-3 (gsk-3) inhibitors | IPSEN PHARMA S.A.S. (FR) | 2004-03-11 | — | — | US | claimed |
| EP-1345941-A1 | CYCLIN-DEPENDENT KINASE (CDK) AND GLYCOLENE SYNTHASE KINASE-3 (GSK-3) INHIBITORS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2003-09-24 | — | — | EP | claimed |
| WO-2002050079-A1 | CYCLIN-DEPENDENT KINASE (CDK) AND GLYCOLENE SYNTHASE KINASE-3 (GSK-3) INHIBITORS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2002-06-27 | — | — | WO | claimed |
| US-20040138245-A1 | Product comprising mikanolide, dihydromikanolide or an analogue thereof combine with another anti-cancer agent for therapeutic use in cancer treatment | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-07-15 | — | — | US | disclosed |
| US-20040048849-A1 | Cyclin-dependent kinase (cdk) and glycolene synthase kinase-3 (gsk-3) inhibitors | IPSEN PHARMA S.A.S. (FR) | 2004-03-11 | — | — | US | disclosed |
| EP-1345941-A1 | CYCLIN-DEPENDENT KINASE (CDK) AND GLYCOLENE SYNTHASE KINASE-3 (GSK-3) INHIBITORS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2003-09-24 | — | — | EP | disclosed |
| WO-2002050079-A1 | CYCLIN-DEPENDENT KINASE (CDK) AND GLYCOLENE SYNTHASE KINASE-3 (GSK-3) INHIBITORS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048849-A1 | Cyclin-dependent kinase (cdk) and glycolene synthase kinase-3 (gsk-3) inhibitors | CDK1, CDK3, CDKL3 | CDK2 12/4885GSK3B 25/4885CCNE1 46/4885 |
| US-20040138245-A1 | Product comprising mikanolide, dihydromikanolide or an analogue thereof combine with another anti-cancer agent for therapeutic use in cancer treatment | DTYMK, DGKG, DGKZ | CDK2 567/4885GSK3B 2441/4885CCNE1 698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.